诉讼核心信息 - 针对Replimune Group, Inc (NASDAQ: REPL)的集体诉讼证券欺诈案已启动 [1] - 诉讼旨在为在2024年11月22日至2025年7月21日期间因涉嫌证券欺诈而遭受损失的投资者追回损失 [1] - 投资者申请作为首席原告的截止日期为2025年9月22日 [3] 指控内容 - 指控称被告做出了虚假陈述和/或隐瞒了事实 [2] - 具体指控为被告在知晓或应知晓存在重大问题的前提下，仍轻率地高估了IGNYTE临床试验的前景 [2] - 该行为导致美国食品药品监督管理局（FDA）认定IGNYTE试验不充分且未得到良好控制 [2] - 因此，被告关于公司业务、运营和前景的陈述在所有相关时间均存在重大虚假和误导性且/或缺乏合理依据 [2]

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. ("Unicycive Therapeutics, Inc." or the "Company") (NASDAQ: UNCY) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Unicycive Therapeutics, Inc. investors who were adversely affected by alleged securities fraud between March 29, 2024 and June 27, 2025. Follow the link below to get more information and be contacted by a member of our team: ...

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/altimmune-inc-lawsuit-subm ...

诉讼背景 - 律所Levi & Korsinsky代表Biohaven Ltd投资者提起集体诉讼 诉讼针对2023年3月24日至2025年5月14日期间因证券欺诈遭受损失的投资者 [1] 指控内容 - 公司被指控夸大治疗脊髓小脑共济失调(SCA)的药物troriluzole的监管前景和提交数据的充分性 [2] - 公司被指控夸大治疗双相情感障碍的药物BHV-7000的疗效和临床前景 [2] - 上述问题曝光后可能对公司业务和财务状况产生重大负面影响 [2] - 被告的公开陈述在所有相关时间均存在重大虚假和误导性 [2] 诉讼程序 - 投资者需在2025年9月12日前申请成为首席原告 [3] - 集体成员可能无需支付自付费用即可获得补偿 [3] 律所资质 - Levi & Korsinsky过去20年为受损股东追回数亿美元资金 [4] - 该律所在美国证券诉讼律师事务所中连续七年跻身ISS证券集体诉讼服务Top 50报告 [4] - 拥有70多名员工组成的团队 在复杂证券诉讼方面具有丰富经验 [4]

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant ...

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/ ...

公司调查事件 - Frank R Cruz律师事务所宣布对Quanex Building Products Corporation展开调查 涉及公司可能违反联邦证券法的行为 [1] - 调查针对因投资Quanex遭受损失的投资者 可能通过索赔追回损失 [1] - 调查直接关联2025年9月4日公司发布的信息 [1]

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 12, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Biohaven Ltd. ("Biohaven†or the "Company†) (NYSE: BHVN) securities between March 24, 2023 and May 14, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO LOST MONEY ON BIOHAVEN LTD. (BHVN), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAU. ...

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lantheus Holdings, Inc. (“Lantheus” or “the Company”) (NASDAQ: LNTH) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lant ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nutex Health Inc. (NASDAQ: NUTX). Shareholders who purchased shares of NUTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/nutex-health-inc-loss-submission-form/?id=16 ...